image
Healthcare - Biotechnology - NASDAQ - US
$ 2.7
-4.59 %
$ 291 M
Market Cap
-1.03
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one RCKT stock under the worst case scenario is HIDDEN Compared to the current market price of 2.7 USD, Rocket Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one RCKT stock under the base case scenario is HIDDEN Compared to the current market price of 2.7 USD, Rocket Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one RCKT stock under the best case scenario is HIDDEN Compared to the current market price of 2.7 USD, Rocket Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart RCKT

image
$14.0$14.0$12.0$12.0$10.0$10.0$8.0$8.0$6.0$6.0$4.0$4.0$2.0$2.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
0 REVENUE
0.00%
-273 M OPERATING INCOME
-5.22%
-259 M NET INCOME
-5.35%
-210 M OPERATING CASH FLOW
-7.60%
132 M INVESTING CASH FLOW
234.30%
186 M FINANCING CASH FLOW
-10.87%
0 REVENUE
0.00%
-64.4 M OPERATING INCOME
-2.70%
-61.3 M NET INCOME
-1.67%
-55.8 M OPERATING CASH FLOW
-18.85%
-58 M INVESTING CASH FLOW
-53.24%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Rocket Pharmaceuticals, Inc.
image
Current Assets 378 M
Cash & Short-Term Investments 372 M
Receivables 0
Other Current Assets 5.85 M
Non-Current Assets 150 M
Long-Term Investments 0
PP&E 83.3 M
Other Non-Current Assets 66.2 M
70.56 %15.79 %12.54 %Total Assets$527.7m
Current Liabilities 40.7 M
Accounts Payable 0
Short-Term Debt 2.86 M
Other Current Liabilities 37.8 M
Non-Current Liabilities 23.8 M
Long-Term Debt 0
Other Non-Current Liabilities 23.8 M
4.43 %58.68 %36.89 %Total Liabilities$64.5m
EFFICIENCY
Earnings Waterfall Rocket Pharmaceuticals, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 273 M
Operating Income -273 M
Other Expenses -14.5 M
Net Income -259 M
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)000(273m)(273m)14m(259m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-55.86% ROE
-55.86%
-49.03% ROA
-49.03%
-55.77% ROIC
-55.77%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Rocket Pharmaceuticals, Inc.
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -259 M
Depreciation & Amortization 9.38 M
Capital Expenditures -5.86 M
Stock-Based Compensation 43.9 M
Change in Working Capital 1.92 M
Others -4.27 M
Free Cash Flow -216 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Rocket Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for RCKT of $26.4 , with forecasts ranging from a low of $2 to a high of $45 .
RCKT Lowest Price Target Wall Street Target
2 USD -25.93%
RCKT Average Price Target Wall Street Target
26.4 USD 878.40%
RCKT Highest Price Target Wall Street Target
45 USD 1566.67%
Price
Max Price Target
Min Price Target
Average Price Target
454540403535303025252020151510105500Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 20
6. Ownership
Insider Ownership Rocket Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
129 K USD 6
3-6 MONTHS
378 K USD 5
6-9 MONTHS
343 K USD 6
9-12 MONTHS
422 K USD 6
Bought
102 K USD 2
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Securities Fraud Investigation Into Rocket Pharmaceuticals, Inc. (RCKT) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ROCKET PHARMACEUTICALS, INC. (RCKT), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What. businesswire.com - 3 days ago
INVESTOR DEADLINE: Rocket Pharmaceuticals, Inc. (RCKT) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Robbins Geller SAN DIEGO, June 20, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the “Class Period”), have until August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. Captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.), the Rocket Pharmaceuticals class action lawsuit charges Rocket Pharmaceuticals as well as one of Rocket Pharmaceuticals' top executives with violations of the Securities Exchange Act of 1934. globenewswire.com - 3 days ago
Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ROCKET PHARMACEUTICALS, INC. (RCKT), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your. businesswire.com - 3 days ago
Faruqi & Faruqi Reminds Rocket Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 - RCKT Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Losses In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Rocket Pharmaceuticals  between February 27, 2025 and May 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). [You may also click here for additional information] NEW YORK , June 20, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) and reminds investors of the August 11, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. prnewswire.com - 3 days ago
Rocket Pharmaceuticals, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Against RCKT SAN DIEGO , June 20, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 7, 2025 and May 26, 2025. Rocket is a fully integrated, late-stage biotechnology company focused on the development of gene therapies, with direct on-target mechanism of action and clear clinical endpoints, for rare and devastating diseases. prnewswire.com - 3 days ago
Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKT NEW YORK , June 20, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Rocket investors who were adversely affected by alleged securities fraud between February 27, 2025 and May 26, 2025. prnewswire.com - 3 days ago
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT NEW YORK, June 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 11, 2025. globenewswire.com - 4 days ago
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit NEW YORK, June 19, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or “the Company”) (NASDAQ: RCKT) and certain of its officers. globenewswire.com - 4 days ago
Shareholders that lost money on Rocket Pharmaceuticals, Inc.(RCKT) Urged to Join Class Action - Contact The Gross Law Firm to Learn More NEW YORK , June 19, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Shareholders who purchased shares of RCKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. prnewswire.com - 4 days ago
ROCKET PHARMACEUTICALS, INC. (NASDAQ: RCKT) INVESTOR ALERT: Investors With Large Losses in Rocket Pharmaceuticals, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights ROCKET PHARMACEUTICALS, INC. (NASDAQ: RCKT) INVESTOR ALERT: Investors With Large Losses in Rocket Pharmaceuticals, Inc. Should Contact Bernstein Liebhard globenewswire.com - 4 days ago
RCKT INVESTOR NOTICE: Robbins Geller Rudman & Dowd Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Rocket Pharm business and prospects, resulting in its stock trading at inflated prices. businesswire.com - 4 days ago
Securities Fraud Investigation Into Rocket Pharmaceuticals, Inc. (RCKT) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ROCKET PHARMACEUTICALS, INC. (RCKT), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On May 27, 2025, Rocket disclosed that the FDA h. businesswire.com - 5 days ago
8. Profile Summary

Rocket Pharmaceuticals, Inc. RCKT

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 291 M
Dividend Yield 0.00%
Description Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
Contact 9 Cedarbrook Drive, Cranbury, NJ, 08512 https://rocketpharma.com
IPO Date Feb. 18, 2015
Employees 299
Officers Dr. Kinnari Patel M.B.A., Pharm.D. Head of R&D, President & Chief Operating Officer Kevin Giordano Director of Corporate Communications Ms. Sarbani Chaudhuri M.B.A. Chief Commercial & Medical Affairs Officer Mr. Aaron Ondrey Chief Financial Officer Dr. Gaurav D. Shah M.D. Chief Executive Officer & Director Dr. Jonathan Schwartz M.D. Chief Medical & Gene Therapy Officer Dr. Gayatri R. Rao J.D., M.D. Senior Vice President of Clinical Safety & Chief Regulatory Officer Ms. Isabel Carmona J.D. Chief People Officer Mr. Martin Louis Wilson J.D. General Counsel, Chief Compliance Officer & Chief Corporate Officer Mr. Raj Prabhakar M.B.A. Chief Business Officer